Mark Baldry
Equibles does not estimate personal net worth.
About Mark Baldry
X4 Pharmaceuticals, Inc reported in an 8-K filed September 17, 2025 that Mark Baldry was terminated as Chief Commercial Officer, effective September 15, 2025. The proxy statement of X4 Pharmaceuticals, Inc reports total compensation of $1,171,703 for Mark Baldry in fiscal 2024, including a base salary of $475,000. Mark Baldry has spoken on 5 earnings calls across 1 company, most recently for X4 Pharmaceuticals, Inc on May 1, 2025. The companies whose calls Mark Baldry spoke on are classified in the Healthcare sector.
“on September 15, 2025, the Board of Directors (the "Board") determined to terminate the employment of Dr. Mary DiBiase, the Company's Chief Operating Officer, Mark Baldry, the Company's Chief Commercial Officer, and Natasha Thoren, the Company's Chief Legal & Compliance Officer, in each case effective as of September 15, 2025.”
Mark Baldry on recent calls
“Ted, I was just going to say we're continuing to build our insights into the CN market itself and actually just completed a large survey with about 95 US physicians who treat chronic neutropenia.”
“You’re right, we’re laser-focused right now on raising disease awareness and driving screening for WHIM and presenting XOLREMDI as a treatment that has proven to work in WHIM.”
“Ted, we had a terrific meeting at CIS in Minneapolis last week. We debuted our now approved booth, and there was lots of excitement and enthusiasm around there.”
“And what’s been interesting is through our disease awareness campaign, we’ve really seen that light bulb go on as we highlight the fact that these patients can present very differently.”
“We thought it would be helpful to start by highlighting some of the ways that we’ve been engaging with the WHIM community, developing an understanding of the market landscape and establishing a foundation for a successful introduction of mavorixafor to physicians, patients, and payers.”
Affiliation history
-
X4 Pharmaceuticals, Inc (XFOR)
Proxy statement
Start not stated–2025-09-15
Company network
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | X4 Pharmaceuticals, Inc (XFOR) | Chief Commercial Officer The amounts reported in the “Options Awards” column reflect the aggregate grant date fair value of stock appreciation rights (“SARs”) and/or stock options awarded during the applicable fiscal year, computed in accordance with the provisions of ASC 718 but disregarding any estimate of forfeitures related to service-based vesting conditions for this purpose. See Note 15 to the X4 Pharmaceuticals Inc. Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 26, 2025, regarding assumptions underlying the valuation of equity awards. The amounts reported in this column reflect the accounting expense for these options and/or SARs and do not correspond to the actual economic value that may be received by our NEOs upon the exercise of the options or SARs, as applicable, or any sale of the underlying shares of common stock. The amounts reported in the “Non-Equity Incentive Plan Compensation” column represent amounts earned pursuant to our annual bonus program, which is based upon our NEO’s achievement of predetermined individual and/or company-wide performance goals. Amounts listed for fiscal year 2024, represents amounts earned for the 12-month period from January 1, 2024 to December 31, 2024 and paid in 2025. See “Narrative to Summary Compensation Table—Non-Equity Incentive Plan Compensation” below for more information. The amounts reported in the “All Other Compensation” column for fiscal year 2024 reflect 401(k) matching contributions of $13,800 for Dr. Ragan and Mr. Baldry, respectively, and the value of group term life insurance provided to each NEO. The amount reported represents a discretionary bonus earned by Mr. Mostafa in 2024 in recognition of his contributions to the sale of a rare pediatric disease priority review voucher for a lump sum payment of $105.0 million in May 2024 (the “PRV Sale”). Mr. Baldry commenced employment with us on November 3, 2022 and was not a NEO for 2023. | $475,000 | $1,171,703 |